US FDA Board Formed To Manage Increasingly Complex Pharmaceutical Supply Chain Oversight
High-level board will bring together information from across FDA drug center and work to increase supply chain transparency, says CDER’s Jacqueline Corrigan-Curay.
You may also be interested in...
Like COVID-19 Impact On Supply Chain, Expert Says Global Demand For Goods ‘Unprecedented’
UCLA professor Chris Tang says like most US businesses relying on supplies or production from outside the country, particularly from China, consumer health and beauty and personal care product companies should expect at least another year of supply disruption.
Cavazzoni Begins Putting Her Mark On FDA Drug Center With New Principal Deputy Position
Jacqueline Corrigan-Curay brings a broad array of policy experience, from trial design to real-world evidence to supply chain and post-market surveillance, to the CDER principal deputy director role, though US FDA is not yet able to articulate exactly what her promotion will entail.
Public-Private Consortium To Strengthen Essential Medicines Supply Under White House Initiative
President Biden’s 100-day plan relies on Defense Production Act authorities to increase resilience of critical domestic pharmaceutical supplies.